Cancer-related immune antigens in the tumor microenvironment could represent an obstacle to agents targeting EGFR "cetuximab" or VEGF "bevacizumab" in metastatic colorectal cancer (mCRC) patients.

Cancer-related CD15/FUT4 overexpression decreases benefit to agents targeting EGFR or VEGF acting as a novel RAF-MEK-ERK kinase downstream regulator in metastatic colorectal cancer

Parcesepe, Pietro;REMO, Andrea;BONETTI, Andrea;MANFRIN, Erminia;Ghasemi, Somayehsadat;BAZZONI, Flavia;
2015-01-01

Abstract

Cancer-related immune antigens in the tumor microenvironment could represent an obstacle to agents targeting EGFR "cetuximab" or VEGF "bevacizumab" in metastatic colorectal cancer (mCRC) patients.
2015
ERBB3 or FGFR4
CD15/FUT4
EGFR or VEGF
Metastatic CRC
File in questo prodotto:
File Dimensione Formato  
2015_JExpClinCancerRes_Giordano et al.pdf

solo utenti autorizzati

Descrizione: Articolo principale
Tipologia: Documento in Post-print
Licenza: Accesso ristretto
Dimensione 2.55 MB
Formato Adobe PDF
2.55 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11562/928277
Citazioni
  • ???jsp.display-item.citation.pmc??? 32
  • Scopus 63
  • ???jsp.display-item.citation.isi??? 56
social impact